Workshop Announcement

Ramon Tate tate at
Wed May 19 14:57:06 EST 1993



               sponsered jointly by


                July 28-30, 1993

            Lister Hill Auditorium
         National Library of Medicine
         National Institutes of Health
              Bethesda, Maryland

Workshop Co-Chairmen:
Sudhir Srivastava, Ph.D.
Donald Henson, M.D.


The Workshop is sponsered by the National Cancer Institute Division of Cancer
Prevention and Control. The goals of the Workshop are to review new technology
for computer-assisted detection and staging of cancer, and to determine whether
patient outome can be predicted with greater certainty.

For registration information, please contact:

Dr. Sudhir Srivastava,
National Cancer Institute
National Institutes of Health
Bethesda, MD 20892
Telephone: (301) 496-8544
FAX: (301) 496-8667

There is no registration fee for the workshop. Special  rates are available at
the Holiday Inn in Bethesda, MD at $98.00  per night, which includes breakfast
and transportation to and from  Lister Hill. The hotel telephone number is
(301) 652-2000; please refer to group 3608. Participants are requested to make
their own reservations.


The growing use of computers by biologists, physicians, epidemiologists and
investigators has been phenomenal. Inexpensive yet powerful microcomputers,
coupled with sophisticated, user-friendly, commercially available software have
largely contributed to this growth. Hospitals, clinical laboratories, and
health care providers have increasingly taken advantage of computer technology
for their database management, information processing, and decision-making
needs. However, computer applications for decision-making in cancer patient
management, in automation and interpretation of laboratory tests for early
detection and diagnosis of cancer, and for prediction of survival based on
multiple indicators are relatively new.

The need for such applications has long been felt by medical communities. Yet
few decision-aids have been developed and applied in early detection,
diagnosis, staging, and laboratory testing. Diagnosic procedures include and
evaluation of the affected tissues, assessment of the extent of disease both
grossly and microscopically, and in some cases, application to special tests.
The current practice of staging and classification of cancer patients is based
on the anatomic extent of disease, which does not incorporate other prognostic
indicators. In the present era of molecular pathology, pathologist may utilize
biomarkers for diagnosis and for estimating outcome. However as the number of
prognostic indicators increases, the decision-making process becomes more
complex. New computer technology can therefore, help pathologists, surgeons,
and oncologists datermine patient outcome with greater certainty and apply
treatment with greater individuality. Also, the computer is increasingly used
in digital image analysis for the measurement, classification, and
determination of DNA content of tumor cells and for the diagnosis of cellular
atypia and precancerous lesions. These have significant implications for
treatment, for example, in differentiating those patients who will benefit the
most from those who will suffer from cancer recurrence.

The Workshop will review new developments in computer programs, methodology,
and technology that can assist physicians in early detection, estimating
prognosis, and tracking the results of screening. This Workshop should help
establish a dialogue among the various federal, academic and commercial groups
involved in artificial intelligence for cancer detection, staging, and


More information about the Bio-soft mailing list